References
- McCulley JP. Blepharoconjunctivitis. Int Ophthalmol Clin 1984;24:65–77
- Leibowitz HM. The red eye. New Engl J Med 2000;343:345–51
- Doan S, Gabison EE, Nghiem-Buffet S, et al. Long-term visual outcome of childhood blepharokeratoconjunctivitis. Am J Ophthalmol 2007;143:528–9
- Hammersmith KM, Cohen EJ, Blake TD, et al. Blepharokeratoconjunctivitis in children. Arch Opthalmol 2005;123:1667–70
- Viswalingam M, Rauz S, Morlet N, Dart JK. Blepharokeratoconjunctivitis in children: diagnosis and treatment. Br J Ophthalmol 2005;89:400–3
- Zylet® Prescribing Information, 2005, Bausch & Lomb Pharmaceuticals, Inc.: Tampa (FL), USA
- TobraDex® Prescribing Information, 2005, Alcon Pharmaceuticals/Laboratories, Inc.: Fort Worth (TX), USA
- Rhee SS, Mah FS. Comparison of tobramycin 0.3%/dexamethasone 0.1% and tobramycin 0.3%/loteprednol 0.5% in the management of blepharokeratoconjunctivitis. Adv Ther 2007;24:60–7
- ICH harmonised tripartite guideline E6: guideline for good clinical practice. London, England: ICH; 2002. Available at: http://www.emea.europa.eu/pdfs/human/ich/013595en.pdf [last accessed September 14, 2007]
- Declaration of Helsinki: ethical principles for medical research involving human subjects. Ferney-Vottaire, France: World Medical Association; 1964. Available at: http://www.wma.net/e/ethicsunit/helsinki.htm [last accessed September 14, 2007]
- Bartlett JD, Howes JF, Ghormley NR, et al. Safety and efficacy of loteprednol etabonate for treatment of papillae in contact lens-associated giant papillary conjunctivitis. Curr Eye Res 1993;12:313–21
- Dell SJ, Shulman DG, Lowry GM, Howes J. A controlled evaluation of the efficacy and safety of loteprednol etabonate in the prophylactic treatment of seasonal allergic conjunctivitis [Loteprednol Allergic Conjunctivitis Study Group]. Am J Ophthalmol 1997;123:791–7
- Loteprednol Etabonate Postoperative Inflammation Study Group 2. A double-masked, placebo-controlled evaluation of 0.5% loteprednol etabonate in the treatment of postoperative inflammation. Ophthalmology 1998;105: 1780–6
- Farpour B, McClellan KA. Diagnosis and management of chronic blepharokeratoconjunctivitis in children. J Pediatr Ophthalmol Strabismus 2001;38:207–12
- Stewart RH, Smith JP, Rosenthal AL. Ocular pressure response to fluorometholone acetate and dexamethasone sodium phosphate. Curr Eye Res 1984;3:198–205
- Holland EJ, Bartlett JD, Paterno MR, et al. The effects of loteprednol/tobramycin versus dexamethasone/tobramycin on intraocular pressure in healthy volunteers. Cornea 2008;27 [doi:10.1097/ICO.0b013e31815873c7]
- Bartlett JD, Horwitz B, Laibovitz R, Howes JF. Intraocular pressure response to loteprednol etabonate in known steroid responders. J Ocul Pharmacol 1993;9:157–65
- Novack GD, Howes J, Crockett RS, Sherwood MB. Change in intraocular pressure during long-term use of loteprednol etabonate. J Glaucoma 1998;7:266–9
- Armaly MF. Statistical attributes of the steroid hypertensive response in the clinically normal eye. I. The demonstration of three level response. Invest Ophthalmol 1963;4:187–97
- Becker B. Intraocular pressure response to topical steroids. Invest Ophthalmol 1965;4:198–205
- Kwok AK, Lam DS, Ng JS, et al. Ocular-hypertensive response to topical steroids in children. Ophthalmology 1997;104:2112–6
- Lam DS, Fan DS, Ng JS, et al. Ocular hypertensive and anti-inflammatory responses to different dosages of topical dexamethasone in children: a randomized trial. Clin Experiment Ophthalmol 2005;33(3):252–8